We are live on ! Find out more
PAI

Palo Alto Investors Portfolio holdings

AUM $654M
1-Year Est. Return 77.8%
This Fund
S&P 500
This Quarter Est. Return
+28.06%
1 Year Est. Return
+77.8%
3 Year Est. Return
+127.05%
5 Year Est. Return
+199.24%
10 Year Est. Return
+2,229.57%
AUM
$1.82B
AUM Growth
+$156M
Cap. Flow
+$13.3M
Cap. Flow %
0.73%
Top 10 Hldgs %
79.73%
Holding
45
New
4
Increased
25
Reduced
5
Closed
2

Top Buys

Rank Stock Value
1
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$33M
2
EHTH icon
eHealth
EHTH
+$22.7M
3
KPTI icon
Karyopharm Therapeutics
KPTI
+$14.1M
4
EPZM
Epizyme, Inc
EPZM
+$11.9M
5
GOSS icon
Gossamer Bio
GOSS
+$11.6M

Top Sells

Rank Stock Value
1
AIMT
Aimmune Therapeutics
AIMT
+$70.2M
2
MNTA
Momenta Pharmaceuticals, Inc.
MNTA
+$49.2M
3
IMMU
Immunomedics Inc
IMMU
+$16.7M
4
RIGL icon
Rigel Pharmaceuticals
RIGL
+$5.79M
5
STAA icon
STAAR Surgical
STAA
+$1.59M

Sector Composition

Rank Sector Weight
1 Healthcare 74.2%
2 Financials 1.22%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ZGNX
26
DELISTED
Zogenix, Inc.
ZGNX
$2.93M 0.16%
163,600
+59,500
+57% +$1.46M
SNDX icon
27
Syndax Pharmaceuticals
SNDX
$1.77B
$2.93M 0.16%
198,400
+70,700
+55% +$1.08M
TVTX icon
28
Travere Therapeutics
TVTX
$5.86B
$2.92M 0.16%
157,900
+110,900
+236% +$2.16M
APRE icon
29
Aprea Therapeutics
APRE
$8.46M
$2.88M 0.16%
5,990
+3,628
+154% +$2.03M
RIGL icon
30
Rigel Pharmaceuticals
RIGL
$782M
$2.84M 0.16%
118,409
-235,846
-67% -$5.79M
CYTK icon
31
Cytokinetics
CYTK
$10.5B
$2.68M 0.15%
123,686
– –
KZR
32
DELISTED
Kezar Life Sciences
KZR
$2.37M 0.13%
48,932
+28,423
+139% +$1.36M
DNTH icon
33
Dianthus Therapeutics
DNTH
$6.29B
$2.34M 0.13%
21,481
+9,318
+77% +$1.1M
TCDA
34
DELISTED
Tricida, Inc. Common Stock
TCDA
$1.55M 0.08%
+170,800
New +$2.49M
EOLS icon
35
Evolus
EOLS
$536M
$1.04M 0.06%
+265,700
New +$971K
ALIM
36
DELISTED
Alimera Sciences
ALIM
$976K 0.05%
200,919
– –
ALDX icon
37
Aldeyra Therapeutics
ALDX
$91.7M
$874K 0.05%
118,000
+44,500
+61% +$287K
AIMT
38
DELISTED
Aimmune Therapeutics
AIMT
$682K 0.04%
19,800
-3,298,412
-99% -$70.2M
URGN icon
39
UroGen Pharma
URGN
$2.39B
$473K 0.03%
24,500
– –
MRNS
40
DELISTED
Marinus Pharmaceuticals, Inc
MRNS
$403K 0.02%
31,330
– –
ACGN
41
DELISTED
Aceragen Inc
ACGN
$165K 0.01%
4,537
– –
VIRX
42
DELISTED
Viracta Therapeutics, Inc. Common Stock
VIRX
$145K 0.01%
33,213
-1
-0% -$9
NERV icon
43
Minerva Neurosciences
NERV
$187M
$115K 0.01%
4,540
– –
ITCI
44
DELISTED
Intra-Cellular Therapies Inc.
ITCI
– –
-37,400
Closed -$960K
MNTA
45
DELISTED
Momenta Pharmaceuticals, Inc.
MNTA
– –
-1,479,524
Closed -$49.2M
1
2

Similar funds

AG
Alibaba Group Causeway Bay, Hong Kong $653M AUM 16.11% 1-Year Est. Return
BL
BWCP LP Dallas, Texas $656M AUM 41.58% 1-Year Est. Return
PIM
Parker Investment Management Menlo Park, California $659M AUM 52.52% 1-Year Est. Return
ACA
Apis Capital Advisors New York $648M AUM 302.67% 1-Year Est. Return
PCM
Primavera Capital Management George Town, Cayman Islands $648M AUM 6.1% 1-Year Est. Return
HCM
Huber Capital Management El Segundo, California $647M AUM 24.91% 1-Year Est. Return
ACM
Arosa Capital Management Miami Beach, Florida $660M AUM 210.26% 1-Year Est. Return
DC
Decheng Capital Menlo Park, California $661M AUM 299.97% 1-Year Est. Return

Palo Alto Investors's Q3 2020 Portfolio in Review

As of Q3 2020, Palo Alto Investors held 45 positions worth $1.82B, up 9.4% from $1.67B the previous quarter. Its ten largest holdings account for 80% of the portfolio.

Palo Alto Investors's Q3 2020 filing shows 4 new, 25 increased, 5 reduced and 2 closed positions. Its largest new stake was eHealth: 280,438 shares worth $22.2M. The largest sale was Aimmune Therapeutics, an estimated $70.2M.

By sector, the portfolio is most concentrated in Healthcare at 74% of assets, down from 84% a quarter earlier, followed by Financials.

  • Palo Alto Investors's largest Q3 2020 buy was eHealth: 280,438 shares worth $22.2M.
  • Palo Alto Investors added most to BioMarin Pharmaceuticals in Q3 2020, an estimated $33M increase.
  • Palo Alto Investors's biggest Q3 2020 reduction was Aimmune Therapeutics, cutting an estimated $70.2M.
  • Palo Alto Investors fully exited Momenta Pharmaceuticals, Inc. in Q3 2020, selling an estimated $49.2M.
  • Palo Alto Investors's ten largest holdings make up 80% of its $1.82B portfolio in Q3 2020.
  • Palo Alto Investors opened 4 new positions and closed 2 in Q3 2020.
  • Palo Alto Investors's portfolio value rose 9.4% quarter-over-quarter to $1.82B.

Based on Palo Alto Investors's 13F filing for Q3 2020, filed 16 Nov 2020.